Clinical trials: Acute Ischemia
Acute Cardiac Ischemia
Evaluation of Patients in Chest Pain in the Emergency Room
The primary objective of this feasibility study is to determine whether it is possible to conduct a study of the ClearView scan among patients under evaluation for acute cardiovascular events, as well as give insight into the…
- Trial name
- EPIC-ER (NCT01476982)
- Testing
- ClearView Scan
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Epic Research & Diagnostics, Inc.
Ischemic Heart Disease, Acute Myocardial Infarction
Safety and Efficacy Study of Gene Therapy for Acute Myocardial Infarction in Korea
The purpose of this study is to evaluate the safety and clinical efficacy of VM202RY injected via transendocardial route using C-Cathez® catheter (Celyad, S.A., Belgium) in subjects with AMI.
- Trial name
- NCT03404024
- Testing
- Stage 1-Low dose VM202RY, Stage 1-Middle dose VM202RY, Stage 1-High dose VM202RY
- Where
- 4 sites in South Korea
- Sponsor
- Helixmith Co., Ltd.
Acute Coronary Syndromes
A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
The purpose of this study is to determine if Apixaban is safer than a Vitamin K Antagonist given for 6 months in terms of bleeding in patients with an irregular heart beat (atrial fibrillation) and a recent heart attack or a…
- Trial name
- NCT02415400
- Testing
- Apixaban, vitamin K antagonist, Acetylsalicylic acid
- Where
- 626 sites in United States, Argentina and 35 more
- Volunteers
- 4,614 people
- Sponsor
- Bristol-Myers Squibb
Cardiovascular Disease
Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study
The primary objective of this trial is to demonstrate the non-inferiority of clopidogrel compared to prasugrel over 6 months in cardiovascular disease patients when the clopidogrel cohort is limited to the estimated 70% of the…
- Trial name
- GeCCO (NCT00995514)
- Where
- United States
- Volunteers
- 4,471 people
- Sponsor
- Medco Health Solutions, Inc.
Atherosclerosis, Acute Coronary Syndrome (ACS)
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
The primary objective of this study is to demonstrate that the efficacy of cangrelor (combined with usual care) is superior to that of usual care, in subjects requiring percutaneous coronary intervention (PCI) as measured by a…
- Trial name
- Platform (NCT00385138)
- Testing
- Cangrelor, clopidogrel
- Where
- United States
- Volunteers
- 5,364 people
- Sponsor
- The Medicines Company
Thrombosis, Acute Coronary Syndrome
Safety, Pharmacokinetic and -Dynamic Study of PR-15, an Inhibitor of Platelet Adhesion
Primary objective: To evaluate safety and tolerability, adverse events (AEs), vital signs, ECG, bleeding time, evaluation of antibody titer and safety laboratory tests Secondary objectives: To evaluate the pharmacokinetics and…
- Conditions
- Thrombosis, Acute Coronary Syndrome, Myocardial Infarction, Stroke
- Trial name
- PR-15/01 (NCT01042964)
- Testing
- revacept (PR-15)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AdvanceCor GmbH
Acute Coronary Syndrome, High Bleeding Risk
LEADERS FREE II: BioFreedom™ Pivotal Study
This study aims to confirm non-inferiority of the BioFreedom™ Drug Coated Stent to the Gazelle™ Bare Metal Stent arm of the Leaders Free study (NCT01623180) in high bleeding risk patients.
- Trial name
- NCT02843633
- Testing
- BioFreedom™ Drug Coated Coronary Stent System, Antiplatelet Drug
- Where
- 66 sites in United States, Canada and 5 more
- Volunteers
- 1,203 people
- Sponsor
- Biosensors Europe SA
Acute Ischemic Stroke
Safety, Performance of CEREGLIDE 92 Intermediate Catheter in Treatment of Acute Ischemic Stroke
The device is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease
- Trial name
- SPLENDID (NCT06386289)
- Testing
- Cereglide 92
- Sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.
Myocardial Infarction
AngioJET Thrombectomy and STENTing for Treatment of Acute Myocardial Infarction
The purpose of this study is to determine whether prompt removal of thrombus (blood clot) from a blocked coronary artery using the AngioJet rheolytic thrombectomy device will result in improved blood flow within the heart and a…
- Trial name
- NCT00275990
- Testing
- rheolytic thrombectomy with direct stenting, direct stenting
- Where
- Italy
- Volunteers
- 501 people
- Sponsor
- Boston Scientific Corporation
Acute Coronary Syndrome
Clinical Study to Validate the Use of a New Point of Care Troponin I Test
This trial is designed as a prospective, multi-center, observational study of "all-comers" eligible adult subjects presenting to participating emergency departments with symptoms suggestive of acute coronary syndrome (ACS)
- Trial name
- NCT02620397
- Where
- 14 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Trinity Biotech
Silent Myocardial Infarction, Stable Angina
Comparative Phase IV Study: Efficacy And Safety of TiTAN2 Versus COBALT-CHROME Stents- EVIDENCEII
The purpose of this study is to compare the effectiveness and safety, at 24 months, of the TITAN2 stent to any bare-metal stent (BMS) in Cobalt-Chromium in a population presenting an indication for these stents among 40% of which…
- Conditions
- Silent Myocardial Infarction, Stable Angina, Acute Coronary Syndrome
- Trial name
- EVIDENCE II (NCT01918150)
- Testing
- Titan 2 stents, Cobalt-Chromium Bare Metal Stents
- Where
- 42 sites in France
- Volunteers
- 1,350 people
- Sponsor
- Hexacath, France
Stroke, Acute Stroke
The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Dimephosphon® in acute ischemic stroke
- Conditions
- Stroke, Acute Stroke, Ischemic Stroke, Cerebrovascular Disorders
- Trial name
- NCT07167550
- Testing
- Dimephosphon®
- Where
- 6 sites in Russia
- Volunteers
- 184 people
- Sponsor
- Tatchempharmpreparaty, JSC
Acute Ischemic Stroke
Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke
The clinical study with UMC119-06 is designed to investigate the safety in patients with acute ischemic stroke ("AIS"). This will be a dose escalation, open-label, single-center study in adult with acute ischemic stroke.
- Trial name
- NCT04097652
- Testing
- UMC119-06
- Where
- Taiwan
- Volunteers
- 9 people
- Sponsor
- Meridigen Biotech Co., Ltd.
Ischemic Heart Disease, Myocardial Ischemia
The Safety and Efficacy of 'AVI' Stent for Treating Coronary Revascularization
The study is a Prospective, Multi-center, Single Armed Registry to Evaluate The Safety and Efficacy of 'AVI' Stent for Treating Coronary Revascularization.
- Conditions
- Ischemic Heart Disease, Myocardial Ischemia, Coronary Disease, Acute Coronary Syndrome
- Trial name
- NCT02117843
- Testing
- AVI® Arsenic trioxide drug eluting stent
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Beijing AmsinoMed Medical Device Co., Ltd
Myocardial Infarction, Glycation End Products, Advanced
Role of Glycation and Inflammation in Acute Ischemic Heart Disease
This study requires the consecutive enrollment of 60 patients following the first event of acute myocardial infarction, evaluating B-Cell Activating Factor (BAFF) and methylglyoxal (MGO) levels in the acute setting…
- Conditions
- Myocardial Infarction, Glycation End Products, Advanced, Inflammation, Heart Injuries
- Trial name
- AGLIANICO (NCT05112731)
- Testing
- BAFF and MGO
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- GEK Srl
Ischemic Stroke
Assess the Penumbra System in the Treatment of Acute Stroke
The purpose of this trial is to assess the safety and effectiveness of the Penumbra System as an adjunctive treatment to intravenous (IV) recombinant human tissue plasminogen activator (rtPA)in patients with acute ischemic stroke…
- Trial name
- THERAPY (NCT01429350)
- Testing
- intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Penumbra System
- Where
- 4 sites in United States
- Volunteers
- 108 people
- Sponsor
- Penumbra Inc.
Stroke, Acute
Detection of hEad Pulse for Ischemic StrOke Verification Study
Prehospital providers encounter patients with suspected stroke frequently. Prehospital providers need tools to help triage large vessel stroke patients to comprehensive stroke centers.
- Trial name
- EPISODE_VS (NCT05602740)
- Testing
- Harmony
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- MindRhythm, Inc.
Myocardial Infarction
A Study of Pre-hospital Treatment of Acute Myocardial Infarction Based on Diagnosis by Interpretation of Remotely Acquired ECG and Thrombolysis With Accelerated Alteplase ( Actilyse®)
The general aim of this study was to assess the feasibility of treating acute myocardial infarction (AMI) by physician-directed pre-hospital thrombosis, using accelerated alteplase (Actilyse®) and a diagnostic technique involving…
- Trial name
- PHARAOH (NCT02235389)
- Testing
- Alteplase (Actilyse), Standard therapy
- Volunteers
- 59 people
- Sponsor
- Boehringer Ingelheim
Dyslipidemia, Atherosclerosis
Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol
The purpose of this study is to investigate an oral formulation of RVX000222 for safety, pharmacokinetic and efficacy in healthy subjects.
- Conditions
- Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome, Cardiovascular Disease
- Trial name
- NCT00768274
- Testing
- RVX000222
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Resverlogix Corp
Acute Myocardial Infarction
Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
This was a double-blind, randomized, placebo-controlled study that was designed to enroll a total of 225 participants with de novo anterior wall acute ST-segment elevation myocardial infarction (STEMI) due to a lesion of the left…
- Trial name
- AMICI (NCT01781390)
- Testing
- Mesenchymal Precursor Cells (MPC) 12.5 M, Mesenchymal Precursor Cells (MPC) 25 M
- Volunteers
- 106 people
- Sponsor
- Mesoblast, Inc.